Press Releases Year All News | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | Nov 10, 2021 TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Nov 01, 2021 TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity Oct 25, 2021 TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors Oct 20, 2021 TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day Oct 13, 2021 TCR² Therapeutics to Host R&D Day on October 20, 2021 Oct 05, 2021 TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy Sep 17, 2021 TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors Sep 13, 2021 TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors Sep 07, 2021 TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference Sep 02, 2021 TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of Cholangiocarcinoma Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »